Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Shares Outstanding (2021 - 2025)

Aligos Therapeutics' Shares Outstanding history spans 5 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 59.87% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, up 59.87%, while the annual FY2025 figure was $6.2 million, 59.87% up from the prior year.
  • Shares Outstanding reached $6.2 million in Q4 2025 per ALGS's latest filing, roughly flat from $6.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $42.9 million in Q1 2023 to a low of $1.7 million in Q4 2022.
  • Average Shares Outstanding over 5 years is $19.0 million, with a median of $6.2 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding: plummeted 95.98% in 2022, then surged 102.03% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $42.7 million in 2021, then tumbled by 95.98% to $1.7 million in 2022, then soared by 74.96% to $3.0 million in 2023, then rose by 28.65% to $3.9 million in 2024, then soared by 59.87% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Shares Outstanding are $6.2 million (Q4 2025), $6.2 million (Q3 2025), and $6.2 million (Q2 2025).